Will we see any revenues from the use of our services in both life sciences and CET divisions David has stated that this will be happening, think that we should have billed clients in the 2nd quarter to reflect this in the 4c. Revenue from sales of anteobind to SII and India, also AnteoX to EV and battery collaborators Or will we get the same old Fluff and promises, that never seem to eventuate Clock is ticking and so far the commercialisation hasn’t produced It is a red hot buy at these prices, the flood gates are bulging with the weight of revenue about to flow down the Anteo gorge. In my Opinion anyway
ADO Price at posting:
2.1¢ Sentiment: Buy Disclosure: Held
